Urogen Pharma: Drops to 4-month low after mid-stage trial disappoints

UroGen Pharma

27/08/2020 15:21

** U.S. shares of Israeli drug developer  URGN.O  down 9.8%
at $20.075, their lowest in more than four months
    ** Co says mid-stage trial of its RTGel formulation in
combination with BOTOX, for patients with overactive bladder and
urinary incontinence, did not meet the main goal of the study
 urn:newsml:reuters.com:*:nBwbW4zW4a
    ** URGN says co's financial position would not be affected
    ** Stock set for its worst session in more than 4 months;
down 33.3% YTD

 (Reporting by Niket Nishant in Bengaluru)
 ((Niket.Nishant@thomsonreuters.com;))